Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Receives $8.50 Average Target Price from Analysts

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) has been given an average recommendation of “Hold” by the seven brokerages that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating and five have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $8.50.

A number of equities research analysts have weighed in on AUTL shares. Wall Street Zen lowered Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Autolus Therapeutics in a report on Wednesday, January 21st. HC Wainwright initiated coverage on Autolus Therapeutics in a research note on Tuesday, February 17th. They issued a “buy” rating and a $9.00 price target on the stock. Zacks Research lowered Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, January 21st. Finally, Needham & Company LLC cut their price objective on Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, January 12th.

Autolus Therapeutics Stock Down 1.2%

Shares of Autolus Therapeutics stock opened at $1.60 on Wednesday. The firm has a market cap of $425.82 million, a price-to-earnings ratio of -1.93 and a beta of 1.95. Autolus Therapeutics has a 52-week low of $1.11 and a 52-week high of $2.70. The company’s 50-day simple moving average is $1.57 and its 200-day simple moving average is $1.53.

Hedge Funds Weigh In On Autolus Therapeutics

Large investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd lifted its stake in shares of Autolus Therapeutics by 334.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 123,279 shares of the company’s stock valued at $245,000 after purchasing an additional 94,873 shares during the period. Invesco Ltd. increased its holdings in Autolus Therapeutics by 35.7% in the fourth quarter. Invesco Ltd. now owns 51,642 shares of the company’s stock valued at $103,000 after buying an additional 13,593 shares in the last quarter. Tudor Investment Corp ET AL lifted its position in shares of Autolus Therapeutics by 36.5% during the 4th quarter. Tudor Investment Corp ET AL now owns 282,113 shares of the company’s stock valued at $561,000 after acquiring an additional 75,460 shares during the period. Armistice Capital LLC boosted its stake in shares of Autolus Therapeutics by 12.2% during the 4th quarter. Armistice Capital LLC now owns 17,500,000 shares of the company’s stock worth $34,825,000 after acquiring an additional 1,900,000 shares in the last quarter. Finally, Cetera Investment Advisers grew its holdings in shares of Autolus Therapeutics by 37.3% in the 4th quarter. Cetera Investment Advisers now owns 1,099,750 shares of the company’s stock worth $2,189,000 after acquiring an additional 298,500 shares during the period. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.